SPEECH-PROCESSING-SOLUTI
Philips Speech by Speech Processing Solutions, a globally leading innovator in voice technology, has announced that they are taking their cooperation with Sembly AI further by extending their audio recorder range with another three new products. Each new recorder is designed to cover different consumer needs and is equipped with Sembly vouchers for users to experience Sembly's new AI capabilities with a free trial version.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625566533/en/
Philips VoiceTracer Audio Recorders (Photo: Business Wire)
Excellent audio recording paired with AI technology
"We are delighted to announce that our partnership with Sembly AI opens up new market opportunities by combining the best of both worlds. By providing top-of-the-line audio recorders paired with an AI meeting assistant, we can offer automatic transcriptions, summaries, and action lists for every recording, whether it’s a lecture or a meeting,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions. “Our innovative solutions enable busy professionals to save time and conduct meetings more efficiently than ever,” he adds.
The new Philips VoiceTracer Audio Recorder DVT4115 and DVT6115, designed for students, boast 3MICs for long-distance recording, ideal for capturing lectures and interviews. Sembly can then transcribe and summarize these recordings. The new Philips VoiceTracer DVT8115, equipped with a 360° microphone, is perfect for recording meeting minutes, with Sembly's easy share function to promptly distribute minutes and action steps to team members. These devices are part of a broader Philips product range, designed to meet diverse recording needs.
Sembly AI offers more than just meeting minutes
The Sembly AI tech startup, founded in 2019, has expanded to offer a wide range of features, including automatic transcription with speaker separation, meeting notes, summaries, and action points. One of the newest innovations is that Sembly AI can now also offer professional AI insights into meetings and conversations, enabling efficient collaboration and streamlined decision-making.
“Our latest AI technology seamlessly integrates with Philips products, adding value whether customers are in the office or on the go. Sembly AI now offers much more than just meeting minutes and we are fully committed to offer new AI services in the coming weeks and months,” explains Gil Makleff, CEO and Co-founder of Sembly AI. “We are proud to collaborate with Philips to enhance the customer experience, empowering users to unlock the full potential of their audio recordings and maximize productivity,” he adds.
These new devices join Philips’ existing portfolio of audio recorders and conference microphones, all compatible with Sembly AI’s software. To discover the entire range of Philips & Sembly products, visit: www.voicetracer.com
About Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.
Follow Us:
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/
About Sembly AI
Sembly AI is a voice and conversation analytics technology company, focused on bringing the power of natural language processing to professional meeting environments. Sembly’s products can simplify the work life of distributed teams while providing powerful analytics to help teams attend less while getting more done. Sembly AI was founded by CEO Gil Makleff and CPO Artem Koren in 2019. Gil Makleff was CEO of UMT Consulting Group which was acquired by Ernst & Young. Artem Koren was a Senior Manager at Ernst & Young and CTO at Visual Trading Systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625566533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release
SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom